Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1401287 | 0.98 | GAA (0.75) | GAANPC1TAAR1CD44HSP90AA1 | |
| SCHEMBL29466462 | 0.88 | GAA (0.83) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| SCHEMBL29601238 | 0.88 | NPC1 (1.00) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| SCHEMBL108063 | 0.88 | NPC1 (1.00) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| SCHEMBL92047 | 0.88 | GAA (1.00) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| SCHEMBL9116148 | 0.88 | NPC1 (0.83) | GAANPC1TAAR1CD44HSP90AA1 | |
| SCHEMBL92067 | 0.88 | GAA (0.83) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL5011472 | 0.86 | GAA (0.79) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL3276689 | 0.86 | NPC1 (0.95) | GAANPC1TAAR1HSP90AA1HSP90AB1 | |
| SCHEMBL16200090 | 0.84 | GAA (0.69) | GAANPC1TAAR1CD44HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| CN-106414448-B | It can be used as the new compound of S100- inhibitor | 活跃生物技术有限公司 | 2019-04-19 | — | — | CN | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3102637-B1 | METHOD FOR PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS OR ENGINEERED VARIANTS THEREOF USING SPECIFIC ANTHRAQUINONE DYE-LIGAND STRUCTURES | BASF SE (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| US-4008225-A | Process for the manufacture of bis-azomethine metal complex colorants | CIBA-GEIGY CORPORATION (US) | 1977-02-15 | — | — | US | disclosed |
| US-3963708-A | Bis-azomethine metal complex colorants from hydroxycoumarin derivatives or hydroxychromone derivatives | CIBA-GEIGY CORPORATION (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | GAA 264/4885NPC1 3302/4885TAAR1 4742/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | GAA 352/4885NPC1 2551/4885TAAR1 4354/4885 |
| US-20180030036-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | GAA 1302/4885NPC1 701/4885TAAR1 4681/4885 |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | GAA 3652/4885NPC1 467/4885TAAR1 257/4885 |
| US-10189819-B2 | Factor IXa inhibitors | F9, TFPI, F12 | GAA 1302/4885NPC1 701/4885TAAR1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.